HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 069294.Supplemental data All Versions of this Article: clinchem.2006.069294v1 52/8/1501    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by de Bont, J. M. Articles by Pieters, R. Search for Related Content PubMed PubMed Citation Articles by de Bont, J. M. Articles by Pieters, R. Related Collections Proteomics and Protein Markers

Identification of Apolipoprotein A-II in Cerebrospinal Fluid of Pediatric Brain Tumor Patients by Protein Expression Profiling

¹ Erasmus MC—Sophia Children’s Hospital—University Medical Center Rotterdam, Department of Pediatric Oncology and Hematology, Rotterdam, The Netherlands.
² Ciphergen Biosystems Inc., Fremont, CA.
Erasmus MC—University Medical Center Rotterdam, Departments of³ Clinical Chemistry,⁴ Pathology, and⁵ Neuro-oncology, Rotterdam, The Netherlands.

^aAddress correspondence to this author at: Erasmus MC—Sophia Children’s Hospital, Department of Pediatric Oncology and Hematology, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. Fax 31-104089433; e-mail m.l.denboer{at}erasmusmc.nl.

Background: Our aim was to detect differences in protein expression profiles of cerebrospinal fluid (CSF) from pediatric patients with and without brain tumors.

Methods: We used surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry and Q10 ProteinChip arrays to compare protein expression profiles of CSF from 32 pediatric brain tumor patients and 70 pediatric control patients. A protein with high discriminatory power was isolated and identified by subsequent anion-exchange and reversed-phase fractionation, gel electrophoresis, and mass spectrometry. The identity of the protein was confirmed by Western blotting and immunohistochemistry.

Results: Of the 247 detected protein peak clusters, 123 were differentially expressed between brain tumor and control patients with a false discovery rate of 1%. Double-loop classification analysis gave a mean prediction accuracy of 88% in discriminating brain tumor patients from control patients. From the 123 clusters, a highly overexpressed protein peak cluster in CSF from brain tumor patients was selected for further analysis and identified as apolipoprotein A-II. Apolipoprotein A-II expression in CSF was correlated with the CSF albumin concentration, suggesting that the overexpression of apolipoprotein A-II is related to a disrupted blood–brain barrier.

Conclusions: SELDI-TOF mass spectrometry can be successfully used to find differentially expressed proteins in CSF of pediatric brain tumor and control patients. Apolipoprotein A-II is highly overexpressed in CSF of pediatric brain tumor patients, which most likely is related to a disrupted blood–brain barrier. Ongoing studies are aimed at finding subtype specific proteins in larger groups of pediatric brain tumor patients.

The following articles in journals at HighWire Press have cited this article:

				H. Dihazi, G. A. Muller, S. Lindner, M. Meyer, A. R. Asif, M. Oellerich, and F. Strutz Characterization of Diabetic Nephropathy by Urinary Proteomic Analysis: Identification of a Processed Ubiquitin Form as a Differentially Excreted Protein in Diabetic Nephropathy Patients Clin. Chem., September 1, 2007; 53(9): 1636 - 1645. [Abstract] [Full Text] [PDF]